The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.

We evaluated an imidazole, cytochrome P 450 -related inhibitor, CGS 16949A, in post-menopausal patients with metastatic breast cancer. CGS 16949A is a potent inhibitor of the corticosterone methyloxidase type II enzyme at a dose of 16 mg daily. At doses of 1-2 mg daily, CGS 16949A blocks aromatase without altering basal aldosterone production and, thus, exhibits dose-related specificity